Latest & greatest articles for menopause

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on menopause or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on menopause and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for menopause

43. Duration of Menopausal Vasomotor Symptoms Over the Menopause Transition

Duration of Menopausal Vasomotor Symptoms Over the Menopause Transition 25686030 2015 04 07 2015 06 29 2016 10 19 2168-6114 175 4 2015 Apr JAMA internal medicine JAMA Intern Med Duration of menopausal vasomotor symptoms over the menopause transition. 531-9 10.1001/jamainternmed.2014.8063 The expected duration of menopausal vasomotor symptoms (VMS) is important to women making decisions about possible treatments. To determine total duration of frequent VMS (≥ 6 days in the previous 2 weeks (...) ) (hereafter total VMS duration) during the menopausal transition, to quantify how long frequent VMS persist after the final menstrual period (FMP) (hereafter post-FMP persistence), and to identify risk factors for longer total VMS duration and longer post-FMP persistence. The Study of Women's Health Across the Nation (SWAN) is a multiracial/multiethnic observational study of the menopausal transition among 3302 women enrolled at 7 US sites. From February 1996 through April 2013, women completed a median

EvidenceUpdates2015

44. The effectiveness of exercise as treatment for vasomotor menopausal symptoms: randomised controlled trial

The effectiveness of exercise as treatment for vasomotor menopausal symptoms: randomised controlled trial 25516405 2015 02 23 2015 04 27 2017 03 22 1471-0528 122 4 2015 Mar BJOG : an international journal of obstetrics and gynaecology BJOG The effectiveness of exercise as treatment for vasomotor menopausal symptoms: randomised controlled trial. 565-75 10.1111/1471-0528.13193 To investigate the effectiveness of exercise as treatment for vasomotor menopausal symptoms. Three-group randomised (...) controlled trial, two exercise interventions and a control group. Primary Care, West Midlands UK. Perimenopausal and postmenopausal women experiencing at least five hot flushes/night sweats per day and not taken MHT in previous 3 months were recruited from 23 general practices. Participants in both exercise interventions groups were offered two face-to-face consultations with a physical activity facilitator to support engagement in regular exercise. In addition, one exercise group received a menopause

EvidenceUpdates2015

45. Menopause

Menopause Menopause - NICE CKS Clinical Knowledge Summaries Share Menopause - Summary Menopause is a biological stage in a woman's life when menstruation ceases permanently due to the loss of ovarian follicular activity. It occurs with the final menstrual period and is usually diagnosed clinically after 12 months of amenorrhoea. In the UK, the mean age of the natural menopause is 51 years, although this can vary between different ethnic groups. Perimenopause is the period before the menopause (...) when the endocrinological, biological, and clinical features of approaching menopause commence. It is characterized by irregular cycles of ovulation and menstruation and ends 12 months after the last menstrual period. Postmenopause is the time after a woman has not had a period for 12 consecutive months. Premature menopause is usually defined as menopause occurring before the age of 40 years. Alterations in hormonal levels result in menopausal symptoms. Vasomotor symptoms (hot flushes and night

NICE Clinical Knowledge Summaries2015

47. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society

Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society

The North American Menopause Society2015

53. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial.

Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. BACKGROUND: Whether menopausal hormone therapy (MHT) protects against cardiovascular disease (CVD) remains unclear. OBJECTIVE: To assess atherosclerosis progression and CVD risk factors after MHT initiated in early menopause. DESIGN: Randomized, controlled trial. (ClinicalTrials.gov: NCT00154180 ). SETTING: Nine U.S. academic centers. PARTICIPANTS: Healthy menopausal women aged 42 to 58

Annals of Internal Medicine2014

54. Palbociclib for advanced ER-positive/HER2-negative breast cancer in post-menopausal women ? first line in combination with letrozole

Palbociclib for advanced ER-positive/HER2-negative breast cancer in post-menopausal women ? first line in combination with letrozole Palbociclib for advanced ER-positive/HER2-negative breast cancer in post-menopausal women – first line in combination with letrozole Palbociclib for advanced ER-positive/HER2-negative breast cancer in post-menopausal women – first line in combination with letrozole NIHR HSC Record Status This is a bibliographic record of a published health technology assessment (...) from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Palbociclib for advanced ER-positive/HER2-negative breast cancer in post-menopausal women – first line in combination with letrozole. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2014 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Antineoplastic Agents; Breast Neoplasms; Female; Humans Language Published English

Health Technology Assessment (HTA) Database.2014

55. Denosumab versus bisphosphonates for the treatment of osteoporosis in post-menopausal women

Denosumab versus bisphosphonates for the treatment of osteoporosis in post-menopausal women Denosumab versus bifosfonatos para el tratamiento de la osteoporosis en mujeres post menopáusicas [Denosumab versus bisphosphonates for the treatment of osteoporosis in post-menopausal women] Denosumab versus bifosfonatos para el tratamiento de la osteoporosis en mujeres post menopáusicas [Denosumab versus bisphosphonates for the treatment of osteoporosis in post-menopausal women] Pichon Riviere (...) en mujeres post menopáusicas. [Denosumab versus bisphosphonates for the treatment of osteoporosis in post-menopausal women] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rápida N° 308. 2013 Authors' objectives To assess the available evidence on the efficacy, safety and coverage policy related aspect for denosumab versus bisphosphonates in decreasing the risk of fractures due to post-menopausal osteoporosis. Authors' conclusions

Health Technology Assessment (HTA) Database.2014

56. Randomised controlled trial: Menopausal hormone therapy has risks and benefits during the intervention and poststopping phase

Randomised controlled trial: Menopausal hormone therapy has risks and benefits during the intervention and poststopping phase Menopausal hormone therapy has risks and benefits during the intervention and poststopping phase | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password (...) ? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Menopausal hormone therapy has risks and benefits during the intervention and poststopping phase Article Text Prevention Randomised controlled trial Menopausal hormone therapy has risks and benefits during the intervention and poststopping phase Michelle P Warren Statistics from

Evidence-Based Medicine (Requires free registration)2014

57. Oral progesterone for the treatment of menopausal symptoms: a review of the clinical evidence

Oral progesterone for the treatment of menopausal symptoms: a review of the clinical evidence Oral progesterone for the treatment of menopausal symptoms: a review of the clinical evidence Oral progesterone for the treatment of menopausal symptoms: a review of the clinical evidence CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation (...) CADTH. Oral progesterone for the treatment of menopausal symptoms: a review of the clinical evidence. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2014 Authors' conclusions Conjugated equine estrogens plus medroxyprogesterone (MPA) did not increase the risk of developing atrial fibrillation, increased the risk of invasive breast cancer, and increased the incidence of deaths attributed to lung cancer compared to placebo in the Women's Health Initiative study

Health Technology Assessment (HTA) Database.2014

58. Oral progesterone for the treatment of menopausal symptoms: clinical evidence

Oral progesterone for the treatment of menopausal symptoms: clinical evidence Oral progesterone for the treatment of menopausal symptoms: clinical evidence Oral progesterone for the treatment of menopausal symptoms: clinical evidence CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Oral progesterone for the treatment (...) of menopausal symptoms: clinical evidence. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2014 Authors' conclusions One systematic review, 23 publications from randomized controlled trials, and two non-randomized studies were identified regarding the clinical efficacy of micronized progesterone or medroxyprogesterone, or the comparative clinical efficacy of micronized progesterone versus medroxyprogesterone, for the management of menopausal symptoms. Final publication

Health Technology Assessment (HTA) Database.2014

60. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society

Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society

The North American Menopause Society2014